Price
$0.49
Increased by +2.04%
Dollar Volume
130.31 K
ADR%
11.61
Earnings Report Date (estimate)
Mar 21, 23 (-0.19)
Market Cap.
33.18 M
Shares Float
39.07 M
Shares Outstanding
67.72 M
Beta
1.05
Price / Earnings
-0.41
BPR
175.32
20D Range
0.33 0.52
50D Range
0.22 0.52
200D Range
0.20 1.09
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.23
Increased by +25.81%
-0.24
Increased by +4.17%
Aug 4, 22 -0.26
Increased by +10.34%
-0.28
Increased by +7.14%
May 12, 22 -0.29
Decreased by -31.82%
-0.30
Increased by +3.33%
Mar 23, 22 -0.29
Decreased by -45.00%
-0.35
Increased by +17.14%
Nov 9, 21 -0.31
Decreased by -29.17%
-0.31
Aug 10, 21 -0.29
Decreased by -7.41%
-0.25
Decreased by -16.00%
May 13, 21 -0.22
Increased by +35.29%
-0.22
Mar 24, 21 -0.20
Increased by +51.22%
-0.24
Increased by +16.67%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
0.00
Increased by +100.00%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-17.67 M
Increased by +10.86%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-19.83 M
Decreased by -39.37%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
0.00
Increased by +100.00%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-21.23 M
Decreased by -87.26%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
-19.82 M
Decreased by -58.34%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 1.00 M
Increased by +22.25%
-14.23 M
Increased by +3.29%
Decreased by -1.42 K%
Increased by +20.89%
Dec 31, 20 0.00
Decreased by -100.00%
-11.49 M
Increased by +16.62%
Decreased by -734.53 B%
Decreased by -48.94 B%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.